EU Pharma Reform
EU Pharma Reform: Lawyers Unpack Diverging Visions For Innovation
Celex Oncology Innovations Ltd was recently highlighted in Pink Sheet’s article, “EU Pharma Reform: Lawyers Unpack Diverging Visions for Innovation,” where we shared our insights on harmonising HTA, incentive models and launch strategies across Europe.
This spotlight aligns perfectly with our core mission at Celex Oncology:
⚕️Bioelectric‑driven oncology: We’re pioneering inhibitors of voltage-gated sodium channels (VGSCs), such as Nav 1.5, which uniquely target tumour cell aggression, a mechanism backed by strong preclinical and real-world data
⚕️Transforming metastatic care: Our proprietary pipeline targeting tumour metastasis is advancing through preclinical stages toward clinical development.
⚕️European expansion and equity: As EU regulations evolve, our work underscores why coherent HTA frameworks and pan-EU launch incentives are vital to ensure innovative, life-extending therapies like ours reach every patient in Europe without delay
With the EU refining its pharma package and global market access trends intensifying, Celex Oncology stands ready to deliver on its promise: turning invasive tumours benign, extending life and preserving quality through groundbreaking science and strategic launch excellence.
➡️Read the full Pink Sheet feature to discover how we’re shaping the future of oncology innovation and access in Europe. Connect with us to explore opportunities for collaboration, investment or partnership.